留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码
x

扩散加权成像表观扩散系数在乳腺癌中的应用进展

孙芳芳 高峰 耿军祖

孙芳芳, 高峰, 耿军祖. 扩散加权成像表观扩散系数在乳腺癌中的应用进展[J]. 分子影像学杂志, 2020, 43(4): 647-650. doi: 10.12122/j.issn.1674-4500.2020.04.20
引用本文: 孙芳芳, 高峰, 耿军祖. 扩散加权成像表观扩散系数在乳腺癌中的应用进展[J]. 分子影像学杂志, 2020, 43(4): 647-650. doi: 10.12122/j.issn.1674-4500.2020.04.20
Fangfang SUN, Gaofeng YI, Junzu GENG. Progress in the application of apparent diffusion coefficient of diffusion weighted imaging in breast cancer[J]. Journal of Molecular Imaging, 2020, 43(4): 647-650. doi: 10.12122/j.issn.1674-4500.2020.04.20
Citation: Fangfang SUN, Gaofeng YI, Junzu GENG. Progress in the application of apparent diffusion coefficient of diffusion weighted imaging in breast cancer[J]. Journal of Molecular Imaging, 2020, 43(4): 647-650. doi: 10.12122/j.issn.1674-4500.2020.04.20

扩散加权成像表观扩散系数在乳腺癌中的应用进展

doi: 10.12122/j.issn.1674-4500.2020.04.20
详细信息
    作者简介:

    孙芳芳,住院医师,E-mail: sff940617@sina.com

    通讯作者:

    耿军祖,硕士,主任医师,E-mail: gengjz001@126.com

Progress in the application of apparent diffusion coefficient of diffusion weighted imaging in breast cancer

  • 摘要: 目的  乳腺癌已成为中国女性最常见的癌症,乳腺MRI在乳腺疾病的诊断中越来越重要。MRI在诊断乳腺癌时有较高的敏感性,但是特异性低,因此扩散加权成像(DWI)作为乳腺MRI的一种重要补充技术,可以提高其特异性,已经在临床中得到广泛应用。表观扩散系数(ADC)是衡量组织中水分子扩散的指标,可通过DWI图像计算获得。DWI-ADC值在鉴别乳腺良恶性病变及评估乳腺癌预后、转移风险、新辅助化疗疗效及乳腺癌筛查等方面的研究成为热点。基于这一领域的最新研究成果,本文将从DWI-ADC的基本原理、2.1-2.5标题加入、局限性及展望进行综述。

     

  • [1] Allarakha A, Gao Y, Jiang H, et al.Predictive ability of DWI/ADC and DCE-MRI kinetic parameters in differentiating benign from malignant breast lesions and in building a prediction model[J].Discov Med, 2019, 27(148):139-52. https://www.ncbi.nlm.nih.gov/pubmed/31095923
    [2] 吴佩琪.影像组学在乳腺癌淋巴结转移中的研究进展[J].分子影像学杂志, 2020, 43(1):31-5. doi: 10.12122/j.issn.1674-4500.2020.01.07
    [3] Vilgrain V, Esvan M, Ronot M, et al.A meta-analysis of diffusionweighted and gadoxetic acid-enhanced MR imaging for the detection of liver metastases[J].Eur Radiol, 2016, 26(12):4595-615. doi: 10.1007/s00330-016-4250-5
    [4] 李海英, 张义钊, 刘鹏, 等.磁共振动态增强联合多b值扩散加权成像诊断乳腺癌的价值[J].中国医学影像学杂志, 2019, 27(12):901-4. https://www.zhangqiaokeyan.com/academic-journal-cn_chinese-journal-medical-imaging_thesis/0201273516106.html
    [5] Hatakenaka M, Soeda H, Yabuuchi H, et al.Apparent diffusion coefficients of breast tumors:clinical application[J].Magn Reson Med Sci, 2008, 7(1):23-9. http://www.ncbi.nlm.nih.gov/pubmed/18460845/
    [6] Surov A, Clauser P, Chang YW, et al.Can diffusion-weighted imaging predict tumor grade and expression of Ki-67 in breast cancer?A multicenter analysis[J].Breast Cancer Res, 2018, 20(1):58. doi: 10.1186/s13058-018-0991-1
    [7] Min QH, Shao KW, Zhai LL, et al.Differential diagnosis of benign and malignant breast masses using diffusion-weighted magnetic resonance imaging[J].World J Surg Oncol, 2015, 13:32. doi: 10.1186/s12957-014-0431-3
    [8] 贺丽英, 潘克梫, 郭佑民.DWI与DCE-MRI联合应用对乳腺良恶性病变鉴别诊断价值的Meta分析[J].实用放射学杂志, 2016, 32(11):1696-701. doi: 10.3969/j.issn.1002-1671.2016.11.012
    [9] 艾娜娜, 张伟, 王德友, 等.MR扩散加权成像ADC值对乳腺占位性病变的诊断价值[J].临床放射学杂志, 2019, 38(6):1006-9. http://www.cnki.com.cn/Article/CJFDTotal-LCFS201906016.htm
    [10] Akin Y, Ugurlu MU, Kaya HD, et al.Diagnostic value of diffusionweighted imaging and apparent diffusion coefficient values in the differentiation of breast lesions, histpathologic subgroups and correlatıon with prognostıc factors using 3.0 tesla MR[J].J Breasth Health, 2016, 12(3):123-32. doi: 10.5152/tjbh.2016.2897
    [11] Li L, Wang K, Sun X, et al.Parameters of dynamic contrastenhanced MRI as imaging markers for angiogenesis and proliferation in human breast cancer[J].Med Sci Monit, 2015, 21:376-82. doi: 10.12659/MSM.892534
    [12] 杨立光, 周倩, 李启霖, 等.功能成像技术对乳腺癌新辅助化疗后疗效评估的研究进展[J].分子影像学杂志, 2019, 42(3):285-9. doi: 10.12122/j.issn.1674-4500.2019.03.01
    [13] 郭宁, 李静, 张仁知, 等.MRI在乳腺黏液癌与T2WI高信号纤维腺瘤中的诊断价值[J].放射学实践, 2019, 34(6):629-34. http://www.cnki.com.cn/Article/CJFDTotal-FSXS201906006.htm
    [14] Tezcan Ş, Uslu N, Öztürk FU, et al.Diffusion-weighted imaging of breast cancer:Correlation of the apparent diffusion coefficient value with pathologic prognostic factors[J].Eur J Breast Health, 2019, 15(4):262-7. doi: 10.5152/ejbh.2019.4860
    [15] 谢宗玉, 程流泉, 杨镇.乳腺浸润性导管癌磁共振扩散加权成像表观扩散系数与预后因子表达的关联性分析[J].中国医学影像学杂志, 2015, 23(3):183-7.
    [16] Suo S, Zhang D, Cheng F, et al.Added value of mean and entropy of apparent diffusion coefficient values for evaluating histologic phenotypes of invasive ductal breast cancer with MR imaging[J].Eur Radiol, 2019, 29(3):1425-34. doi: 10.1007/s00330-018-5667-9
    [17] 尚柳彤, 杨家斐, 卢晶, 等.磁共振扩散加权成像表观扩散系数与肿块型浸润性乳腺癌分子亚型的相关性[J].南方医科大学学报, 2017, 37(10):1410-4. doi: 10.3969/j.issn.1673-4254.2017.10.22
    [18] Kawai M, Kataoka M, Kanao S, et al.The value of lesion size as an adjunct to the BI-RADS-MRI 2013 descriptors in the diagnosis of solitary breast masses[J].Magn Reson Med Sci, 2018, 17(3):203-10. doi: 10.2463/mrms.mp.2017-0024
    [19] Park SH, Choi HY, Hahn SY.Correlations between apparent diffusion coefficient values of invasive ductal carcinoma and pathologic factors on diffusion-weighted MRI at 3.0 Tesla[J].J Magn Reson Imaging, 2015, 41(1):175-82. doi: 10.1002/jmri.24519
    [20] Kim EJ, Kim SH, Park GE, et al.Histogram analysis of apparent diffusion coefficient at 3.0t:Correlation with prognostic factors and subtypes of invasive ductal carcinoma[J].J Magn Reson Imaging, 2015, 42(6):1666-78. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC162794/
    [21] Ren CC, Zou Y, Zhang XD, et al.Diagnostic value of diffusionweighted imaging-derived apparent diffusion coefficient and its association with histological prognostic factors in breast cancer[J].Oncol Lett, 2019, 18(3):3295-303. doi: 10.3892/ol.2019.10651
    [22] 柴瑞梅, 王欣, 黄德生, 等.DWI评价乳腺浸润性导管癌生物学特征[J].中国医学影像技术, 2017, 33(8):1232-6. doi: 10.13929/j.1003-3289.201701046
    [23] Belli P, Costantini M, Bufi E, et al.Diffusion magnetic resonance imaging in breast cancer characterisation:correlations between the apparent diffusion coefficient and major prognostic factors[J].La Radiol Med, 2015, 120(3):268-76. doi: 10.1007/s11547-014-0442-8
    [24] Ludovini V, Sidoni A, Pistola L, et al.Evaluation of the prognostic role of vascular endothelial growth factor and microvessel density in stages I and II breast cancer patients[J].Breast Cancer Res Treat, 2003, 81(2):159-68. doi: 10.1023/A:1025755717912
    [25] Catalano OA, Horn GL, Signore A, et al.PET/MR in invasive ductal breast cancer:correlation between imaging markers and histological phenotype[J].Br J Cancer, 2017, 116(7):893-902. doi: 10.1038/bjc.2017.26
    [26] Petrelli F, Viale G, Cabiddu M, et al.Prognostic value of different cutoff levels of Ki-67 in breast cancer:a systematic review and metaanalysis of 64, 196 patients[J].Breast Cancer Res Treat, 2015, 153(3):477-91. doi: 10.1007/s10549-015-3559-0
    [27] Parker JS, Mullins M, Cheang MC, et al.Supervised risk predictor of breast cancer based on intrinsic subtypes[J].J Clin Oncol, 2009, 27(8):1160-7. doi: 10.1200/JCO.2008.18.1370
    [28] Liu SG, Ren RM, Chen ZQ, et al.Diffusion-weighted imaging in assessing pathological response of tumor in breast cancer subtype to neoadjuvant chemotherapy[J].J Magn Reson Imaging, 2015, 42(3):779-87. doi: 10.1002/jmri.24843
    [29] Yuan CR, Jin F, Guo XL, et al.Correlation analysis of breast cancer DWI combined with DCE-MRI imaging features with molecular subtypes and prognostic factors[J].J Med Syst, 2019, 43(4):83. doi: 10.1007/s10916-019-1197-5
    [30] Rabasco P, Caivano R, Simeon V, et al.Can diffusion-weighted imaging and related apparent diffusion coefficient be a prognostic value in women with breast cancer?[J].Cancer Invest, 2017, 35(2):92-9. doi: 10.1080/07357907.2016.1267740
    [31] Kim JY, Kim JJ, Hwangbo L, et al.Diffusion-weighted imaging of invasive breast cancer:relationship to distant metastasis-free survival[J].Radiology, 2019, 291(2):300-7. doi: 10.1148/radiol.2019181706
    [32] Hu XY, Li Y, Jin GQ, et al.Diffusion-weighted MR imaging in prediction of response to neoadjuvant chemotherapy in patients with breast cancer[J].Oncotarget, 2017, 8(45):79642-9. doi: 10.18632/oncotarget.18999
    [33] Bedair R, Priest AN, Patterson AJ, et al.Assessment of early treatment response to neoadjuvant chemotherapy in breast cancer using non-mono-exponential diffusion models:a feasibility study comparing the baseline and mid-treatment MRI examinations[J].Eur Radiol, 2017, 27(7):2726-36. doi: 10.1007/s00330-016-4630-x
    [34] 佟颖, 米楠, 张荣, 等.磁共振扩散加权成像(DWI)评估进展期乳腺癌患者新辅助化疗近期疗效及病理变化的价值研究[J].影像科学与光化学, 2020, 38(2):307-12. http://www.cnki.com.cn/Article/CJFDTotal-GKGH202002024.htm
    [35] Minarikova L, Bogner W, Pinker K, et al.Investigating the prediction value of multiparametric magnetic resonance imaging at 3 T in response to neoadjuvant chemotherapy in breast cancer[J].Eur Radiol, 2017, 27(5):1901-11. doi: 10.1007/s00330-016-4565-2
    [36] Monticciolo DL, Newell MS, Moy L, et al.Breast cancer screening in women at higher-than-average risk:recommendations from the ACR[J].JAm Coll Radiol, 2018, 15(3 pt a):408-14. doi: 10.1016/j.jacr.2017.11.034
    [37] Yamada T, Kanemaki Y, Okamoto S, et al.Comparison of detectability of breast cancer by abbreviated breast MRI based on diffusion-weighted images and postcontrast MRI[J].Jpn J Radiol, 2018, 36(5):331-9. doi: 10.1007/s11604-018-0731-6
    [38] Amornsiripanitch N, Rahbar H, Kitsch AE, et al.Visibility of mammographically occult breast cancer on diffusion-weighted MRI versus ultrasound[J].Clin Imaging, 2018, 49:37-43. doi: 10.1016/j.clinimag.2017.10.017
    [39] McDonald ES, Hammersley JA, Chou SHS, et al.Performance of DWI as a rapid unenhanced technique for detecting mammographically occult breast cancer in elevated-risk women with dense breasts[J].Am J Roentgenol, 2016, 207(1):205-16. doi: 10.2214/AJR.15.15873
    [40] Baltzer P, Mann RM, Iima M, et al.Diffusion-weighted imaging of the breast-a consensus and mission statement from the EUSOBI international breast diffusion-weighted imaging working group[J].Eur Radiol, 2020, 30(3):1436-50. doi: 10.1007/s00330-019-06510-3
  • 加载中
计量
  • 文章访问数:  733
  • HTML全文浏览量:  334
  • PDF下载量:  17
  • 被引次数: 0
出版历程
  • 收稿日期:  2020-09-08
  • 刊出日期:  2020-10-20

目录

    /

    返回文章
    返回

    关于《分子影像学杂志》变更刊期通知

    各位专家、作者、读者:

    为了缩短出版时滞,促进科研成果的快速传播,我刊自2024年1月起,刊期由双月刊变更为月刊。本刊主要栏目有:基础研究、临床研究、技术方法、综述等。

    感谢各位专家、作者、读者长期以来对我刊的支持与厚爱!

    南方医科大学学报编辑部

    《分子影像学杂志》

    2023年12月27日